Free. Unsubscribe any time.
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. filed 16 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 2 reporting owners, covering 20 transactions and 364,485 shares. 16 carry the SEC's AFF10B5ONE flag; 0 name a plan only in a footnote. 10 results prints are on file in the same window.
What stands out
- The most recent filing on file, dated 2026-09-16, came 13 days after the one before it (2026-09-03) and reports 1 transaction against 3 in the filing before it.
- The sales it reports total 58,333 shares, 57,749 more than the 584 in the filing before it.
- Its 16 plan statements rank 321st of the 483 companies the register carries in Delaware, its state of incorporation.
- Of the 10 companies the register lists beside it in its industry, 4 have more plan statements on file than it and 6 have fewer.
- Its 16 filings on file run from 2025-09-26 to 2026-09-16, and state 3 plan adoption dates, from 2025-06-06 to 2026-01-13.
Trades in 4D Molecular Therapeutics, Inc. 20
- Bizily Scott — 2025-09-23 · S · 2,407 shares
- Bizily Scott — 2025-10-09 · S · 2,408 shares
- Bizily Scott — 2025-10-16 · S · 1,635 shares
- Bizily Scott — 2025-10-24 · S · 2,678 shares
- Bizily Scott — 2025-11-17 · S · 1,635 shares
- Bizily Scott — 2025-12-16 · S · 1,635 shares
- Kirn David — 2026-06-01 · S · 1,922 shares
- Kirn David — 2026-06-22 · S · 114,746 shares
- Bizily Scott — 2026-06-30 · S · 6,566 shares
- Kirn David — 2026-07-09 · S · 42,608 shares
- Kirn David — 2026-07-10 · S · 15,283 shares
- Kirn David — 2026-07-10 · S · 442 shares
Adoption dates in 4D Molecular Therapeutics, Inc. 3
- 2025-06-06 — stated in 6 filings
- 2026-01-09 — stated in 7 filings
- 2026-01-13 — stated in 3 filings
Results prints in 4D Molecular Therapeutics, Inc. 10
- 2025-01-10
- 2025-02-28
- 2025-05-08
- 2025-08-11
- 2025-11-06
- 2025-11-10
- 2026-01-07
- 2026-03-18
- 2026-05-07
- 2026-08-13
Trades before a print in 4D Molecular Therapeutics, Inc. 1
- 0 days before the 2026-08-13 print — 2026-08-13 · S · Bizily Scott · 1,635 shares
- 9 days before the 2026-08-13 print — 2026-08-04 · S · Kirn David · 26,842 shares
- 10 days before the 2026-08-13 print — 2026-08-03 · S · Kirn David · 12,415 shares
- 13 days before the 2025-11-06 print — 2025-10-24 · S · Bizily Scott · 2,678 shares
- 21 days before the 2025-11-06 print — 2025-10-16 · S · Bizily Scott · 1,635 shares
- 22 days before the 2026-01-07 print — 2025-12-16 · S · Bizily Scott · 1,635 shares
- 28 days before the 2025-11-06 print — 2025-10-09 · S · Bizily Scott · 2,408 shares
- 34 days before the 2026-08-13 print — 2026-07-10 · S · Kirn David · 15,283 shares
- 34 days before the 2026-08-13 print — 2026-07-10 · S · Kirn David · 442 shares
- 35 days before the 2026-08-13 print — 2026-07-09 · S · Kirn David · 42,608 shares
- 44 days before the 2025-11-06 print — 2025-09-23 · S · Bizily Scott · 2,407 shares
- 44 days before the 2026-08-13 print — 2026-06-30 · S · Bizily Scott · 6,566 shares
Interval to 4D Molecular Therapeutics, Inc.’s next reported results date
How the interval and sources are counted →
- 1within 5 days
- 3within 10 days
- 0shortest, days
- 5no later print
- Kirn David 2026-08-03 · S · 10 days before the 2026-08-13 print · See Remarks
- Kirn David 2026-08-04 · S · 9 days before the 2026-08-13 print · See Remarks
- Bizily Scott 2026-08-13 · S · 0 days before the 2026-08-13 print · Chief Legal Officer
Adoption dates 4D Molecular Therapeutics, Inc. states
- 2025-06-06 in 6 filings
- 2026-01-09 in 7 filings
- 2026-01-13 in 3 filings
Filing text: “10b5-1 trading plan adopted by the Reporting Person on June 6, 2025”
Reported results dates on file
- 2025-01-10
- 2025-02-28
- 2025-05-08
- 2025-08-11
- 2025-11-06
- 2025-11-10
- 2026-01-07
- 2026-03-18
- 2026-05-07
- 2026-08-13
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 2
- FMC CORP 2
- ELI LILLY & Co 11
- ABEONA THERAPEUTICS INC. 7
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 37
- Lifevantage Corp 3
- IONIS PHARMACEUTICALS INC 86
- VERTEX PHARMACEUTICALS INC / MA 74
- ARROWHEAD PHARMACEUTICALS, INC. 23
Sources: SEC EDGAR full-text search and the SEC submissions API.